Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487276 | 0.77 | ALDH1A1 (0.59) | TDP1ALDH1A1GPR35KDM4EGAA | |
| SCHEMBL17802800 | 0.75 | TDP1 (0.45) | TDP1ALDH1A1GPR35KDM4EMAPT | |
| SCHEMBL28667238 | 0.73 | TSHR (0.41) | TDP1ALDH1A1GPR35KDM4EMAPT | |
| SCHEMBL29444873 | 0.71 | ALDH1A1 (0.53) | TDP1ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL5358624 | 0.71 | ALDH1A1 (0.53) | TDP1ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL29577518 | 0.69 | HSD17B10 (0.67) | TDP1ALDH1A1GPR35HSD17B10TSHR | |
| SCHEMBL16355165 | 0.69 | HSD17B10 (0.67) | TDP1ALDH1A1GPR35HSD17B10TSHR | |
| SCHEMBL22566 | 0.69 | HSD17B10 (0.67) | TDP1ALDH1A1GPR35HSD17B10TSHR | |
| SCHEMBL29064 | 0.69 | — | — | |
| SCHEMBL3831213 | 0.68 | AURKA (0.66) | TDP1ALDH1A1GPR35KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102984943-A | Improved methods for folate targeting agents | ENDOCYTE INC | 2013-03-20 | — | — | CN | claimed |
| EP-1969369-A4 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | SHARP KK (JP) | 2009-04-29 | — | — | EP | claimed |
| EP-1969369-A1 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | Sharp Kabushiki Kaisha (JP) | 2008-09-17 | — | — | EP | claimed |
| WO-2007072973-A1 | NOVEL CAPTURE AGENTS FOR BINDING A LIGAND | SHARP KABUSHIKI KAISHA (JP) | 2007-06-28 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4678240-A2 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | Hangzhou Dac Biotech Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| EP-3319936-B1 | BRIDGE LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | HANGZHOU DAC BIOTECH CO LTD (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-4218562-A | Antibiotic derivatives of XK-62-2 | ABBOTT LABORATORIES (US) | 1980-08-19 | — | — | US | disclosed |
| US-4216309-A | BACTERICIDES | ABBOTT LABORATORIES (US) | 1980-08-05 | — | — | US | disclosed |
| US-4195171-A | Derivatives of an antibiotic XK-62-2 and process for the production thereof | ABBOTT LABORATORIES (US) | 1980-03-25 | — | — | US | disclosed |
| US-4132846-A | BACTERICIDES, AMINOGLYCOSIDE ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1979-01-02 | — | — | US | disclosed |
| US-4109077-A | ANTIBIOTIC DERIVATIVES OF XK-62-2 COMPOUNDS | ABBOTT LABORATORIES (US) | 1978-08-22 | — | — | US | disclosed |
| US-4097664-A | 3\"-N-DEMETHYL- AND 3\"-N, 6'DIDEMETHYL-1-2-HYDROXY-W-AMINOACYL DERIVATIVES | ABBOTT LABORATORIES (US) | 1978-06-27 | — | — | US | disclosed |
| US-4076931-A | Derivatives of an antibiotic XK-62-2 and the process for the production thereof | ABBOTT LABORATORIES (US) | 1978-02-28 | — | — | US | disclosed |
| US-4055715-A | Method of producing 1-N-[L-(-)-α-hydroxy-γ-aminobutyryl]XK-62-2 | ABBOTT LABORATORIES (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | TDP1 3989/4885ALDH1A1 2817/4885GPR35 3003/4885 |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | TDP1 4546/4885ALDH1A1 1399/4885GPR35 1843/4885 |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TDP1 3390/4885ALDH1A1 618/4885GPR35 1827/4885 |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | TDP1 3390/4885ALDH1A1 618/4885GPR35 1827/4885 |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | TDP1 3693/4885ALDH1A1 743/4885GPR35 3618/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | TDP1 3609/4885ALDH1A1 2641/4885GPR35 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.